Emmaus Life Sciences Inc. Announces FDA Advisory Committee Meeting for Endari™ for Sickle Cell Disease Apr 18, 2017 8:00am EDT
Emmaus Life Sciences, Inc. to Present at Los Angeles Biomedical Research Institute's (LA BioMed) Innovation Showcase Mar 08, 2017 8:00am EST
Emmaus Life Sciences, Inc. Receives Notice of Allowance for Japanese Patent for use of L-glutamine in Treatment of Diabetes Feb 07, 2017 8:00am EST
Emmaus Life Sciences, Inc. Receives Notice of Allowance for U.S. Patent for use of L-glutamine in Treatment of Diverticulosis Feb 01, 2017 8:00am EST
Yutaka Niihara, MD, MPH, CEO of Emmaus, Appointed Executive Chairman of Generex Biotechnology Corporation Jan 25, 2017 8:00am EST
Emmaus Life Sciences, Inc. Enters into Collaborative Agreement with Generex Biotechnology Corporation Jan 24, 2017 8:00am EST
Emmaus Life Sciences, Inc. Receives Japanese Patent for use of L-glutamine in Treatment of Diverticulosis Dec 13, 2016 8:00am EST
Emmaus Life Sciences Receives Notice of FDA PDUFA Date for Investigational L-glutamine Treatment for Sickle Cell Disease Nov 29, 2016 8:00am EST
Emmaus' New Drug Application for Sickle Cell Disease Accepted for Review by FDA Nov 08, 2016 8:00am EST
Emmaus Life Sciences Completes $20 Million Private Placement From Two Korean-based Public Companies Oct 03, 2016 8:00am EDT
